🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-527504-24-00
Authorised Phase I

[14C]Navlimetostat Mass Balance Study in Healthy Female Participants

2026-527504-24-00 · tracked via the Priya Life Science EU tracker
Sponsor
Bristol-Myers Squibb Services Unlimited Company
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
24/09/2026
Enrollment target
6
Sites
Netherlands

Condition studied

Advanced Solid Tumors

Eligibility

Age group
18-64 years
Sex
Female
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-527504-24-00 on CTIS ↗ ← All trials in the EU